Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment
Journal article published in 2021 by
Liang Chen 
,
Michael C. Zody,
Clara Di Germanio,
Rachel Martinelli,
Jose R. Mediavilla,
Marcus H. Cunningham,
Kaelea Composto,
Kar Fai Chow,
Milena Kordalewska,
André Corvelo,
Dayna M. Oschwald,
Samantha Fennessey,
Marygrace Zetkulic,
Sophia Dar,
Yael Kramer
and other authors.
,
Michael C. Zody,
Clara Di Germanio,
Rachel Martinelli,
Jose R. Mediavilla,
Marcus H. Cunningham,
Kaelea Composto,
Kar Fai Chow,
Milena Kordalewska,
André Corvelo,
Dayna M. Oschwald,
Samantha Fennessey,
Marygrace Zetkulic,
Sophia Dar,
Yael Kramer
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Over a year of the COVID-19 pandemic, distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages have arisen in multiple geographic areas around the world. SARS-CoV-2 variants of concern (VOCs), i.e., B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta), harboring mutations and/or deletions in spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) regions showed evidence of increased transmissibility and disease severity and possible reduced vaccine efficacy.